: Risk stratification has gained an increasing role in predicting outcomes and guiding the treatment of patients with pulmonary arterial hypertension (PAH). The most predictive prognostic factors are three noninvasive parameters (World Health Organization functional class, 6-min walk distance and natriuretic peptides) that are included in all currently validated risk stratification tools. However, suffering from limitations mainly related to reduced specificity of PAH severity, these variables may not always be adequate in isolation for guiding individualised treatment decisions. Moreover, with effective combination treatment regimens and emerging PAH therapies, markers associated with pulmonary vascular remodelling are expected to become of increasing relevance in guiding the treatment of patients with PAH. While reaching a low mortality risk, assessed with a validated risk tool, remains an important treatment goal, preliminary data suggest that invasive haemodynamics and cardiac imaging may add incremental value in guiding treatment decisions.

Dardi, F., Boucly, A., Benza, R., Frantz, R., Mercurio, V., Olschewski, H., et al. (2024). Risk stratification and treatment goals in pulmonary arterial hypertension. EUROPEAN RESPIRATORY JOURNAL, 64(4), 1-22 [10.1183/13993003.01323-2024].

Risk stratification and treatment goals in pulmonary arterial hypertension

Dardi, Fabio
Primo
;
2024

Abstract

: Risk stratification has gained an increasing role in predicting outcomes and guiding the treatment of patients with pulmonary arterial hypertension (PAH). The most predictive prognostic factors are three noninvasive parameters (World Health Organization functional class, 6-min walk distance and natriuretic peptides) that are included in all currently validated risk stratification tools. However, suffering from limitations mainly related to reduced specificity of PAH severity, these variables may not always be adequate in isolation for guiding individualised treatment decisions. Moreover, with effective combination treatment regimens and emerging PAH therapies, markers associated with pulmonary vascular remodelling are expected to become of increasing relevance in guiding the treatment of patients with PAH. While reaching a low mortality risk, assessed with a validated risk tool, remains an important treatment goal, preliminary data suggest that invasive haemodynamics and cardiac imaging may add incremental value in guiding treatment decisions.
2024
Dardi, F., Boucly, A., Benza, R., Frantz, R., Mercurio, V., Olschewski, H., et al. (2024). Risk stratification and treatment goals in pulmonary arterial hypertension. EUROPEAN RESPIRATORY JOURNAL, 64(4), 1-22 [10.1183/13993003.01323-2024].
Dardi, Fabio; Boucly, Athénaïs; Benza, Raymond; Frantz, Robert; Mercurio, Valentina; Olschewski, Horst; Rådegran, Göran; Rubin, Lewis J.; Hoeper, Mari...espandi
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/996655
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact